For the treatment of moderate to severe hidradenitis suppurativa (HS) in patients 12 years of age and older


99% of national commercial patients have coverage for HUMIRA as a preferred, first-line* targeted immunomodulator on formulary.2

National commercial health plan formulary status under the pharmacy benefit in HS as of August 2022


1% non-preferred


National commercial formulary status under the pharmacy benefit as of August 2022.

*Formulary Definitions: Preferred means the product is placed on the plan's preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit or are placed on a higher tier. Preferred products may also require a step edit depending on the product’s label. First-line refers to a preferred or parity formulary status.
Disadvantaged means a restriction (eg, prior authorization, step edit, quantity limits, or other medical policies) to a product that is not applied consistently across the entire therapeutic class.

Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.